30 March 2020
PsoProtect: a new psoriasis and COVID-19 patient registry
The Psoriasis Association are pleased to announce their support for PsoProtect.
The Psoriasis Association are pleased to announce their support for PsoProtect, an international registry where health care professionals can report outcomes of COVID-19 infection in people with psoriasis.
PsoProtect
has been set up by
world-leading psoriasis researchers at Guy’s and St Thomas’ NHS
Foundation Trust, King’s College London, and the University of
Manchester to capture de-identified
information about the
outcomes and experiences of
individuals with psoriasis
who have had COVID-19.
This will
provide real world information for clinicians to help them assess
risk in people with
psoriasis. The registry will
also help researchers to investigate whether
different medicines or co-morbidities of psoriasis affect the outcome
of COVID-19 infection.
This registry will provide a vital clinical and research resource to help in our collective fight against COVID-19 but please note that the registry is for clinicians to submit de-identified data, not patients. However, if you or a family member with psoriasis have had, or get Coronavirus, please do ask your clinician to submit your data to PsoProtect.
PsoProtect will publish regular summaries and insights from the registry, however, they are unable to provide information on request. The latest data can be found here.
In October 2020, the first findings from PsoProtect were published. You can find out more here.
For the most up-to-date advice on COVID-19 (Coronavirus), you should:
- Read the guidance on the NHS website
- Read the guidance on the Public Health England website